Columbus

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• HIV3 trials
• Lupus (SLE)3 trials
• Asthma2 trials
• COPD2 trials
• Multiple myeloma2 trials
• Ovarian cancer2 trials
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Irritable bowel syndrome1 trial
• Lung cancer1 trial
• Sickle cell disease1 trial

Phase

• Phase 37 trials
• Phase 25 trials
• Phase 14 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting9 trials
• Completed6 trials
• Recruiting4 trials
• Terminated1 trial

Lead sponsor

• GlaxoSmithKline13 trials
• Tesaro, Inc.4 trials
• ViiV Healthcare3 trials

Running trials

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

  Contact: Jose Bazan (principal investigator)

• Recruiting

  A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

  NCT07519395· Phase 2· GlaxoSmithKline· Source

  Contact: Ryan Gaible (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

  NCT06741397· Phase 2· ViiV Healthcare· Source

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Yvonne Efebera (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

  NCT06694805· Phase 3· ViiV Healthcare· Source

• Recruiting

  Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

  NCT06527872· GlaxoSmithKline· Source

  Contact: Isabelle Ayoub (principal investigator)

• Active, not recruiting

  A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

  NCT06576271· Phase 1· GlaxoSmithKline· Source

• Active, not recruiting

  REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

  NCT06041386· Phase 4· GlaxoSmithKline· Source

• Active, not recruiting

  A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

  NCT06154837· Phase 1· GlaxoSmithKline· Source

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

  NCT06062420· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

  NCT03981796· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

  NCT02655016· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV1 recruiting
• Irritable bowel syndrome1 recruiting
• Lupus (SLE)1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Terminated

  A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

  NCT05660265· Phase 1· GlaxoSmithKline· Source

• Completed

  A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

  NCT05496231· Phase 1/2· GlaxoSmithKline· Source

• Completed

  Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04719832· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

  NCT03525678· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

  NCT03326193· Phase 2· Tesaro, Inc.· Source

• Completed

  Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

  NCT01729455· GlaxoSmithKline· Source